Robeco Institutional Asset Management B.V. Purchases 1,053,482 Shares of Pfizer Inc. (NYSE:PFE)

Robeco Institutional Asset Management B.V. increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 16.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,431,299 shares of the biopharmaceutical company's stock after purchasing an additional 1,053,482 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.13% of Pfizer worth $188,309,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer in the fourth quarter worth $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the fourth quarter worth about $30,000. Institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on PFE shares. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.04 during trading on Thursday, reaching $24.30. The company's stock had a trading volume of 31,721,433 shares, compared to its average volume of 41,253,215. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The firm has a market cap of $138.18 billion, a PE ratio of 17.61, a P/E/G ratio of 0.88 and a beta of 0.57. The business's 50-day moving average price is $23.38 and its 200-day moving average price is $24.87. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the previous year, the firm posted $0.82 EPS. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.08%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.